Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2023-07-21 Report Publication Anno…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
EQS-News: BB BIOTECH AG: Sektorrotation und Kapitalabflüsse belasten Biotechaktien, doch positive Entwicklungen ermöglichen Kapitalbeschaffung zur Stärkung der Industrie
Report Publication Announcement Classification · 95% confidence The document is a press release titled 'Zwischenbericht der BB Biotech AG per 30. Juni 2023' (Interim Report of BB Biotech AG as of June 30, 2023). While it contains some financial highlights and portfolio data, it explicitly states at the end that the full interim report is available via a link ('Der vollständige Zwischenbericht... ist auf... verfügbar'). According to the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 words) that directs the reader to the full report, it is classified as a Report Publication Announcement (RPA). H1 2023
2023-07-21 German
EQS-Adhoc: BB Biotech AG pubblica il proprio rapporto intermedio
Report Publication Announcement Classification · 99% confidence The document is an 'Ad hoc announcement' published on 21.07.2023. The primary subject is the publication of the 'rapporto intermedio al 30 giugno 2023' (interim report as of June 30, 2023), which covers the first half of 2023 financial performance. This clearly identifies the document as a comprehensive financial report for a period shorter than a year. According to the definitions, this corresponds to the Interim / Quarterly Report (IR). Although it announces the report, the text also contains key financial highlights (loss of CHF 267 million) and is structured as a formal regulatory disclosure (pursuant to Art. 53 LR and Art. 17 MAR), making it more than just a simple 'Report Publication Announcement' (RPA). It also contains a secondary announcement about delisting from Borsa Italiana, but the primary focus is the interim financial results announcement.
2023-07-21 Italian
EQS-Adhoc: BB Biotech AG publishes its interim report
Report Publication Announcement Classification · 99% confidence The document is an 'Ad hoc announcement' dated July 21, 2023, which explicitly states: 'BB Biotech AG publishes its interim report' for the period ended June 30, 2023. It provides key financial highlights (net loss) and a link to the full interim report. Since the document itself is an announcement about the publication of a report, and it contains financial results for a period shorter than a year (H1 2023), it aligns best with the Interim / Quarterly Report (IR) category, as it is the announcement of that report. However, given the short length (3526 chars) and the explicit mention of publishing the report and providing links, the 'Report Publication Announcement' (RPA) category is also highly relevant based on Rule 2. Since the core content is the release of the H1 financial results, IR is the primary subject, but RPA captures the *format* of the filing. Given the context of financial reporting, the release of an 'interim report' strongly points to IR. If the document were just a one-liner saying 'The IR is available,' RPA would be stronger. Since it contains the key figures, IR is the most appropriate classification for the *content* being released, even if announced via an ad-hoc filing. I will classify it as IR because it contains the core financial summary of the interim period, not just a notice of publication.
2023-07-21 English
EQS-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
Delisting Announcement Classification · 99% confidence The document is titled 'Ad hoc-Mitteilung' (Ad hoc announcement) and explicitly states that 'BB Biotech AG veröffentlicht Zwischenbericht' (BB Biotech AG publishes Interim Report) for the period ending June 30, 2023. This content describes the results of a period shorter than a year (1st half-year 2023) and is a comprehensive financial report for that period, fitting the definition of an Interim/Quarterly Report (IR). Although it announces the publication, the text contains substantial financial details (loss after tax of CHF 267 Mio.) and is not merely a brief notification pointing to an attachment, thus it is classified as the report content itself, not just an RPA. The document also contains a separate announcement regarding a delisting, but the primary focus and headline relate to the interim financial results.
2023-07-21 German
Half-yearly financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at 30.06.2023' and contains a comprehensive table of contents covering business performance, shareholder letters, consolidated interim financial statements, and auditor reports. It provides substantive financial data, performance metrics, and management analysis for the six-month period ending June 30, 2023. It is not an announcement or a certification, but the full interim report itself. H1 2023
2023-07-21 English
BB BIOTECH AG: Creating blockbuster drugs using algorithms
Regulatory Filings Classification · 99% confidence The document is dated May 3, 2023, and is distributed via EQS News. The content is an expert commentary titled 'BB BIOTECH AG: Creating blockbuster drugs using algorithms' discussing investment insights, AI in drug discovery, and portfolio company updates. It is not a formal regulatory filing like a 10-K, nor is it a brief announcement of a report (RPA/RNS) as it contains substantial analytical content (9400 characters). It is too detailed for a standard Earnings Release (ER) which usually contains only key figures. Since it provides detailed analysis and commentary on the company's investment strategy, portfolio, and market outlook, it most closely aligns with an Investor Presentation (IP) or a detailed Management Discussion/Analysis (MDA). Given the format is an expert commentary/article rather than a structured presentation deck, and it discusses investment strategy and portfolio performance insights, it fits best as a form of Investor Information. However, looking at the definitions, it is an in-depth article providing insights relevant to investors, which often accompanies or substitutes for a formal Investor Presentation (IP) or a detailed Management Report (MDA). Since it is an article/commentary focusing on investment themes and portfolio activity, and not a formal financial results release, 'Investor Presentation' (IP) is the most appropriate fit for detailed, forward-looking investment commentary outside of mandated financial reports.
2023-05-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.